JP2023538130A - 神経疾患のための組成物および方法 - Google Patents

神経疾患のための組成物および方法 Download PDF

Info

Publication number
JP2023538130A
JP2023538130A JP2023512700A JP2023512700A JP2023538130A JP 2023538130 A JP2023538130 A JP 2023538130A JP 2023512700 A JP2023512700 A JP 2023512700A JP 2023512700 A JP2023512700 A JP 2023512700A JP 2023538130 A JP2023538130 A JP 2023538130A
Authority
JP
Japan
Prior art keywords
receptor
engineered
ligand
human
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538130A5 (https=
Inventor
アンソニー ジュニア ラウ，
オリオン ピー． ジュニア キーファー，
ステファニー マキンソン，
アレクサンダー ナカ，
Original Assignee
トレイムス バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレイムス バイオ， インコーポレイテッド filed Critical トレイムス バイオ， インコーポレイテッド
Publication of JP2023538130A publication Critical patent/JP2023538130A/ja
Publication of JP2023538130A5 publication Critical patent/JP2023538130A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023512700A 2020-08-21 2021-08-20 神経疾患のための組成物および方法 Pending JP2023538130A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068890P 2020-08-21 2020-08-21
US63/068,890 2020-08-21
PCT/US2021/046915 WO2022040535A2 (en) 2020-08-21 2021-08-20 Compositions and methods for neurological diseases

Publications (2)

Publication Number Publication Date
JP2023538130A true JP2023538130A (ja) 2023-09-06
JP2023538130A5 JP2023538130A5 (https=) 2024-08-28

Family

ID=80350587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512700A Pending JP2023538130A (ja) 2020-08-21 2021-08-20 神経疾患のための組成物および方法

Country Status (11)

Country Link
US (1) US20240317834A1 (https=)
EP (1) EP4200020A4 (https=)
JP (1) JP2023538130A (https=)
KR (1) KR20230061409A (https=)
CN (1) CN116802201A (https=)
AU (1) AU2021329529A1 (https=)
BR (1) BR112023003167A2 (https=)
CA (1) CA3192604A1 (https=)
IL (1) IL300816A (https=)
MX (1) MX2023002161A (https=)
WO (1) WO2022040535A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487904B (zh) * 2023-12-28 2024-05-31 湖南家辉生物技术有限公司 Gabrb3基因突变体、突变体蛋白、试剂、试剂盒及应用
CN119331917B (zh) * 2024-10-28 2025-10-17 北京爱思益普生物科技股份有限公司 能够表达GlyR α1/β型GlyR的细胞株及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009832A1 (en) * 2016-07-07 2018-01-11 Scott Sternson Modified ligand-gated ion channels and methods of use
US20190161529A1 (en) * 2017-11-27 2019-05-30 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2021035179A1 (en) * 2019-08-21 2021-02-25 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009832A1 (en) * 2016-07-07 2018-01-11 Scott Sternson Modified ligand-gated ion channels and methods of use
US20190161529A1 (en) * 2017-11-27 2019-05-30 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2019104307A1 (en) * 2017-11-27 2019-05-31 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2021035179A1 (en) * 2019-08-21 2021-02-25 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases

Also Published As

Publication number Publication date
WO2022040535A3 (en) 2022-03-31
EP4200020A2 (en) 2023-06-28
BR112023003167A2 (pt) 2023-05-02
US20240317834A1 (en) 2024-09-26
AU2021329529A9 (en) 2025-03-13
EP4200020A4 (en) 2024-11-20
MX2023002161A (es) 2023-05-18
CN116802201A (zh) 2023-09-22
KR20230061409A (ko) 2023-05-08
IL300816A (en) 2023-04-01
WO2022040535A2 (en) 2022-02-24
AU2021329529A1 (en) 2023-04-27
CA3192604A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP2024160218A (ja) 神経疾患のための組成物および方法
JP7781052B2 (ja) 神経学的疾患のための組成物および方法
JP2023538130A (ja) 神経疾患のための組成物および方法
JP2025508429A (ja) 神経学的疾患のための組成物および方法
JP2025508427A (ja) リガンド依存性イオンチャネルおよび使用の方法
BR122025015501A2 (pt) Receptor modificado, polinucleotídeo, vetor, uso dos mesmos, bem como método para expressão de um receptor modificado em um neurônio
CN119343455A (zh) 用于治疗癫痫和神经性疼痛的表达盒
CN116997647A (zh) 用于治疗局灶性癫痫和神经性疼痛的腺相关病毒衣壳和工程化配体门控离子通道

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260212